Thymosin Beta-4 Dosing & Reconstitution Guide
Dosing Protocol
Route: Subcutaneous (systemic) or Topical/Ophthalmic Frequency: SC: Once daily; Ophthalmic: 2x daily Dose Range: SC: 750–2000 mcg/day; Ophthalmic (RGN-259): 0.1% solution 2 drops 2x daily
Safety & Contraindications
Safety: RGN-259 ophthalmic solution was well-tolerated in clinical trials with no significant drug-related adverse events A safety-focused study in 40 healthy adults receiving injectable Tβ4 found minimal adverse effects Topical (eye drop) administration has minimal systemic exposure
Contraindications: Active cancer or history of cancer (theoretical concern due to cell migration promotion); Pregnancy and breastfeeding (no safety data for systemic use)
Related Research News
TB-500: Thymosin Beta-4's Role in Healing and Repair
TB-500, known as thymosin β4, is a 43-amino-acid peptide first isolated from calf thymus in 1966 by Goldstein et al. It regulates actin in the body, supporting processes like wound healing, angiogenesis, and inflammation control. Research highlights its potential in treating conditions such as myocardial infarction, corneal injuries, and lung damage.
BPC-157 + TB-500 Peptide Blend: Research on Healing and Repair
The BPC-157 and TB-500 peptide blend draws attention in research for potential synergy in tissue repair, angiogenesis, and reducing inflammation. BPC-157, a 15-amino-acid synthetic peptide, interacts with growth factors in preclinical models. TB-500, a 43-amino-acid analog of Thymosin Beta-4, supports cell migration and regeneration. Studies explore their roles in wound healing, tendon recovery, and more.